Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant,
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antineoplastic Agents, Immunological
/ administration & dosage
Camptothecin
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Disease-Free Survival
Dose-Response Relationship, Drug
ErbB Receptors
/ antagonists & inhibitors
Female
Humans
Infusions, Intravenous
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Metastasis
Treatment Outcome
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
03
06
2021
revised:
16
08
2021
accepted:
15
09
2021
pubmed:
23
9
2021
medline:
31
3
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most
Identifiants
pubmed: 34548309
pii: 2159-8290.CD-21-0715
doi: 10.1158/2159-8290.CD-21-0715
pmc: PMC9401524
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
patritumab deruxtecan
3XPI7EG4W8
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Camptothecin
XT3Z54Z28A
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-89Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Lung Cancer. 2020 Mar;141:37-43
pubmed: 31945708
Onco Targets Ther. 2018 Apr 12;11:2121-2129
pubmed: 29695919
BMC Pharmacol Toxicol. 2017 May 10;18(1):21
pubmed: 28486985
Oncogene. 2019 Feb;38(9):1398-1409
pubmed: 30302022
Mol Cancer Ther. 2019 Nov;18(11):2043-2050
pubmed: 31395690
Sci Signal. 2009 Jun 30;2(77):ra31
pubmed: 19567914
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Clin Cancer Res. 2019 Dec 1;25(23):7151-7161
pubmed: 31471314
Clin Cancer Res. 2021 Jul 1;27(13):3528-3539
pubmed: 33608318
Sci Rep. 2019 May 15;9(1):7406
pubmed: 31092882
Mol Cancer. 2018 Feb 19;17(1):29
pubmed: 29455654
Clin Cancer Res. 2020 Jun 1;26(11):2654-2663
pubmed: 31911548
J Surg Res. 2008 May 1;146(1):43-8
pubmed: 17631905
Transl Lung Cancer Res. 2016 Dec;5(6):695-708
pubmed: 28149764
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
J Clin Oncol. 2018 Nov 1;36(31):3101-3109
pubmed: 30156984
Chem Pharm Bull (Tokyo). 2019;67(3):173-185
pubmed: 30827997
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33771889
J Clin Oncol. 2010 Jan 10;28(2):357-60
pubmed: 19949011
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Lung Cancer. 2020 May;143:67-72
pubmed: 32213382
Oncotarget. 2017 May 18;8(40):67140-67151
pubmed: 28978022
Lancet Oncol. 2020 Mar;21(3):373-386
pubmed: 32027846
Cancer Res. 2022 Jan 1;82(1):130-141
pubmed: 34548332
Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47
pubmed: 35117062
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
Respirology. 2020 Nov;25 Suppl 2:72-79
pubmed: 32729207
Oncotarget. 2016 Nov 29;7(48):78985-78993
pubmed: 27738317
Crit Rev Oncol Hematol. 2020 Feb;146:102820
pubmed: 31785991
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650